Navigation Links
InterMune Announces Proposed Public Offering of Common Stock
Date:1/19/2010

207';s.tl(this,'o','ExternalLink');" target='_blank' href="mailto:prospectus-ny@ny.email.gs.com">prospectus-ny@ny.email.gs.com or by calling 212-902-1171). InterMune intends to file a prospectus supplement relating to the offering with the SEC, which will be available along with the base prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at http://www.sec.gov/.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  

Forward-Looking Statements  

This announcement contains forward-looking statements, including statements relating to InterMune's expectations regarding the completion, timing and size of the proposed public offering. These statements are subject to significant risks and uncertainties, actual results could differ materially from those projected and InterMune cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. There can be no assurance that InterMune will be able to complete the public offering on the anticipated terms, or at all. If InterMune is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue one or more of its drug development or discovery research programs. Additional risks and uncertainties relating to InterMune and its business can be found in the "Risk Factors" section of InterMune'
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014 Polaris Group announced ... in its Phase 1 trial of ADI-PEG 20 ... treatment of malignant pleural mesothelioma (MPM) and non-squamous ... clinical trials on ADI-PEG 20, both as monotherapy ... treatment of several other indications, including breast cancer, ...
(Date:11/21/2014)... and SAN DIEGO , Nov. ... today announced that President and CEO Marc Hedrick , M.D. ... DATE:   Thursday, December 4, 2014 TIME:    ... here or paste this URL into your browser,s ... that investors pre-register to save time and receive event updates. ...
(Date:11/18/2014)... SAN BRUNO, Calif. , Nov. 18, 2014 ... is a platinum sponsor of the 10th Annual World Stem ... and regenerative medicine stakeholders. The 2014 World Stem Cell Summit ... San Antonio, Texas . ... the discovery and development of lifesaving cures and therapies, convening ...
(Date:11/18/2014)... LA (PRWEB) November 17, 2014 ... build-to-order, open architecture blade-based and rackmount computing infrastructure, ... Tesla® K80 dual-GPU accelerator throughout its GPU-enabled blade ... pair of the company‚Äôs latest proprietary 80-lane Gen3 ... eight discrete NVIDIA Tesla K80 dual-GPU accelerator cards ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
... Ontario, Nov. 6 Helix BioPharma Corp. (TSX, FSE: "HBP" ... and chief operating officer, will present at Merriman Curhan Ford,s ... PM at the Sofitel Hotel in New York City. ... product development programs L-DOS47 and Topical Interferon Alpha-2b. The ...
... - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the ... study of intravenous REOLYSIN(R) in patients with sarcomas metastatic ... 15th Annual Connective Tissue Oncology Society Meeting held in ... poster presentation, entitled "A Phase II Study of Intravenous ...
... The endangered black-footed ferrets inhabit prairie dog towns in the ... The prairie dogs are very susceptible to plague ... U.S. Fish & Wildlife Service (FWS) has implemented a ferret ... their formerly native habitat. Unfortunately, plague can sweep through ...
Cached Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2
(Date:11/7/2014)... BURBANK, Calif. , Nov. 7, 2014  In conjunction ... Burbank Police Departments, The Community Foundation of the ... BURBANK DNA JUSTICE PROJECT," a $250,000 initiative to ... successful initial phase. In its first six months of existence, ... desperately needed evidence support for local law enforcement. ...
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
(Date:11/4/2014)... In nature, the right amount of death at the ... density, according to new research that could help in ... wildlife stocks. , In a paper in the journal ... University researcher and European colleagues conclude that the kind ... a loss of individuals, or mortality, depends on the ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2When less is more: Death in moderation boosts population density in nature 2
... Stephen Moose has developed a corn plant with enormous potential ... silage, Moose said, due to a greater number of leaves ... energy crop. The gene known as Glossy 15 was ... waxy coating that acts like a sun screen for the ...
... for its health benefits. But now scientists have ... produce medicines for several autoimmune and inflammatory diseases, ... open access journal BMC Biotechnology . ... research organizations have participated in the study as ...
... knows, children love sweet-tasting foods. Now, new research ... indicates that this heightened liking for sweetness has a ... rate. "The relationship between sweet preference and growth ... demands increase. Children are programmed to like sweet ...
Cached Biology News:Doubling a gene in corn results in giant biomass 2Tobacco makes medicine 2Liking sweets makes sense for kids 2
Kit containing MACS equipment and reagents for immunopurification of proteins....
... LCMSsolution software offers an intuitive, ... instrument control, diverse data handling, ... requirements. Comprehensive functions include data ... data management in both standalone ...
... a modern flow cytometer, a scientist can ... labeled with fluorescent probes. However, the emission ... cell labeling are broader than the light ... filters. Thus, the fluorescence signal of a ...
... Sigmas FLAG Immunoprecipitation kit allows a ... of an active FLAG-tagged protein. The ... gel, which is a highly specific ... resin. The use of affinity resin ...
Biology Products: